Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2023 21:00 ET | Source: NovalGen Ltd.

NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting

NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222
November 02, 2023 15:18 ET | Source: NovalGen Ltd.

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
January 09, 2023 07:00 ET | Source: NovalGen Ltd.

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today...
November 03, 2022 09:58 ET | Source: NovalGen Ltd.

NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting

-Updated clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL -- Pre-clinical data for a first in class half-life extended T Cell engager...
May 26, 2022 18:00 ET | Source: NovalGen Ltd.

NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting

- First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates promising efficacy with a predictable and...